D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

Inclusion Criteria

• •Patients will be at least 18 years of age.
• •Patients will be experiencing moderate to severe peripheral neuropathic pain
• •Patients may be on chronic adjuvant pain medications such as antidepressants but must be on stable doses for at least one week prior to admission.
• •Patients may be taking concurrent opioids but they must be willing to allow us to monitor their opioid use while on the trial.
• •Patients must have chronic peripheral neuropathic pain will be defined as pain of 3 or more months duration which began in association with chemotherapy.
• •Patient's will have bilateral peripheral neuropathic pain symptoms primarily involving the feet
• •Patients must have breast cancer (any stage)
• •Patients must be able to read and speak English and provide informed consent.
• •Patients may be receiving chemotherapy as long as the agents are not known to cause a peripheral neuropathy.
• •Patients must have an ECOG Performance Status \< 3 and be able to attend the physician study visits
• •Patients must not concurrently use gabapentin or pregabalin or must be willing to wean off their anti-convulsant medications prior to starting the trial.
• •Patients may have diabetes mellitus (type 1 or 2) as long as there is no preexisting neuropathy.